An HIV vaccine has proven successful in a Phase I clinical trial with no adverse effects on human patients. The vaccine, developed by Dr. Chil-Yong Kang and his team at Western’s Schulich School of Medicine & Dentistry, with the support of Sumagen Canada, is the first genetically modified, whole-killed vaccine to be approved for testing in humans.
“We are now prepared to take the next steps towards Phase II and Phase III clinical trials,” Sumagen CEO Jung-Gee Cho said in a press release. “We are opening the gate to pharmaceutical companies, government, and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine.”
This vaccine was used in human clinical trial to evaluate its safety, tolerability and immune responses from March 2012 through August 2013:
This trial was a randomized, observer-blinded, placebo-controlled study of killed whole HIV-1 vaccine (SAV001-H) following intramuscular (IM) administration. HIV-infected, asymptomatic men and women, 18 to 50 years of age, have been enrolled in this study and randomized into two treatment groups to administer killed whole HIV-1 vaccine (SAV001-H) or placebo…No serious adverse event was observed in any volunteer vaccines throughout the observation periods.
Sumagen will now proceed with Phases 2 and 3 clinical trials to show the immunogenicity and efficacy of the vaccine and the pharmaceutical company plans on having not only “the first HIV vaccine in market but also the eradication of HIV/AIDS for human beings.”
h/t: Medical Daily